Waiel Al-Kahiry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Waiel Al-Kahiry has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amal Ghanem
Department of Hematology, Medical Research Institute, University of Alexandria, 47 (A) Memphis - Camp Chezar, Alexandria, Egypt
1 shared publication - Gamal Abdul Hamid
Professor Hematology Oncology, University of Aden, Yemen
1 shared publication H H Omer
1 shared publication- Homam Sharshira
Department of Hematology, Medical Research Institute, University of Alexandria, 47 (A) Memphis - Camp Chezar, Alexandria, Egypt
1 shared publication - Irene Lewis Mikhael
Department of Hematology, Medical Research Institute, Alexandria University, Alexandria, Egypt
1 shared publication - Maha Mohamed Adel Elgammal
Department of Hematology, Medical Research Institute, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
1 shared publication
Latest Publications
- 16 November 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (3) , 321-326
Evaluation of Prognostic Impact of Soluble CD14 in B-Chronic Lymphocytic Leukemia
SCD14 is an acute phase reactant; few studies reported its prognostic value in B-CLL patients. This gave us the impetus to conduct this study. This study enrolled 40 newly diagnosed B-CLL Egyptian patients, presented to the Hematology Department of the Medical Research Institute in Alexandria University. The ZAP-70 was determined by flow cytometry whereas serum sCD14 concentration by human sCD14 sandwich ELISA method. The mean serum level of sCD14 was significantly higher among patients with positive ZAP-70, Binet stage C, Rai stage III–IV and high risk CLL prognostic index. It showed a significant positive correlation to the percentage of ZAP-70 expression and significant negative correlation to the hemoglobin concentration. Serum sCD14 concentration could be used to assess B-CLL patients initially as an additional prognostic marker, especially in low resources areas where flow cytometry is not available.
- 16 November 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (3) , 321-326
Evaluation of Prognostic Impact of Soluble CD14 in B-Chronic Lymphocytic Leukemia
SCD14 is an acute phase reactant; few studies reported its prognostic value in B-CLL patients. This gave us the impetus to conduct this study. This study enrolled 40 newly diagnosed B-CLL Egyptian patients, presented to the Hematology Department of the Medical Research Institute in Alexandria University. The ZAP-70 was determined by flow cytometry whereas serum sCD14 concentration by human sCD14 sandwich ELISA method. The mean serum level of sCD14 was significantly higher among patients with positive ZAP-70, Binet stage C, Rai stage III–IV and high risk CLL prognostic index. It showed a significant positive correlation to the percentage of ZAP-70 expression and significant negative correlation to the hemoglobin concentration. Serum sCD14 concentration could be used to assess B-CLL patients initially as an additional prognostic marker, especially in low resources areas where flow cytometry is not available.
- 18 August 2011
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 28 (1) , 19-23
Hematological Malignancies in Al-Amal Oncology Unit, Aden
The hematological malignancies (HM) are group of neoplasms that arise through malignant transformation of bone marrow derived cells. The great diversity seen in this group of disorders is a reflection of the complexity of normal hematopoiesis and the immune system. In the current study, the author retrospectively studied HM patients from 2008 to 2010, and compared with prevalence of solid tumor, and found HM represented one-fifth of all malignancies managed in the Oncology Unit, and lymphomas were the commonest HM.
- 18 August 2011
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 28 (1) , 19-23
Hematological Malignancies in Al-Amal Oncology Unit, Aden
The hematological malignancies (HM) are group of neoplasms that arise through malignant transformation of bone marrow derived cells. The great diversity seen in this group of disorders is a reflection of the complexity of normal hematopoiesis and the immune system. In the current study, the author retrospectively studied HM patients from 2008 to 2010, and compared with prevalence of solid tumor, and found HM represented one-fifth of all malignancies managed in the Oncology Unit, and lymphomas were the commonest HM.
- 1 January 2011
- No. 9,p. 7-11
Late presentation of breast cancer in Aden, Yemen.
The aim of this study is to determine the frequency and characteristics of patients who presented with late stage breast cancer at Al-Amal Oncology Unit in Aden. It was conducted retrospectively in Aden, at Al-Amal Oncology Unit of Al-Gamhouria Modern General Hospital, by reviewing all records of breast cancer patients at any stage and attended with histopathologically documented breast cancer from the time of establishment of the unit on December 1, 2007 to December 31, 2009. The total number of documented breast cancer patients was 197 and classified according to the stage at presentation and after the exclusion of 21 patients who were not staged. 118 patients with late inoperable stages were selected and carefully evaluated of their demographic characteristics and was found that they represented 67.0% of the total staged breast cancer patients. Most of these patients are in the reproductive age and residents of Aden governorate and neighboring governorates. Metastasis was mainly evident at the lymph nodes, bones, liver and lungs. The case fatality rate for late stage breast cancer is 8.5 per 100 patients. This study concludes that a high percentage of Yemeni patients in Aden presented with late stage breast cancer which led to the failure of possible curative surgical intervention and resulted to high metastatic disease and fatality rate. Late Presentation, Aden, Yemen, Breast Cancer, Stages.
- 1 January 2011
- No. 9,p. 7-11
Late presentation of breast cancer in Aden, Yemen.
The aim of this study is to determine the frequency and characteristics of patients who presented with late stage breast cancer at Al-Amal Oncology Unit in Aden. It was conducted retrospectively in Aden, at Al-Amal Oncology Unit of Al-Gamhouria Modern General Hospital, by reviewing all records of breast cancer patients at any stage and attended with histopathologically documented breast cancer from the time of establishment of the unit on December 1, 2007 to December 31, 2009. The total number of documented breast cancer patients was 197 and classified according to the stage at presentation and after the exclusion of 21 patients who were not staged. 118 patients with late inoperable stages were selected and carefully evaluated of their demographic characteristics and was found that they represented 67.0% of the total staged breast cancer patients. Most of these patients are in the reproductive age and residents of Aden governorate and neighboring governorates. Metastasis was mainly evident at the lymph nodes, bones, liver and lungs. The case fatality rate for late stage breast cancer is 8.5 per 100 patients. This study concludes that a high percentage of Yemeni patients in Aden presented with late stage breast cancer which led to the failure of possible curative surgical intervention and resulted to high metastatic disease and fatality rate. Late Presentation, Aden, Yemen, Breast Cancer, Stages.